Literature DB >> 4398342

Levodopa's awakening effect on patients with Parkinsonism.

G G Marsh, C M Markham, R Ansel.   

Abstract

The effects of levodopa on tests measuring auditory and visual perception, auditory, and visual short-term memory, verbal learning, and on attention and concentration were studied in 29 patients with Parkinsonism. Thirty-two control subjects matched with the Parkinsonism patients on age, educational level, and verbal IQ were administered the same tests to control for practice effects. Significant improvement occurred for the Parkinsonism patients in verbal learning (an intermediate memory test) and in auditory perception. These improvements were unrelated to changes in anticholinergic medications, increases in alertness or concentration, lessening of depression, or improved motor ability or control. There was no test evidence of levodopa improving visual perception, short-term auditory or visual memory, alertness or concentration. Thus, there is no objective test evidence for levodopa producing a generalized awakening or an alerting effect in Parkinsonism patients who are intellectually alert and well-orientated. Interpretation of the test findings suggests a specific awakening effect, that of improvement in intermediate memory but not in short-term memory. Overall, the Parkinsonism group scored below the control group on all tests, suggesting that cognitive impairment accompanies Parkinson's disease even in patients who are intellectually intact and well oriented.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4398342      PMCID: PMC1083453          DOI: 10.1136/jnnp.34.3.209

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  Depressive symptoms in Parkinson patients referred for thalamotomy.

Authors:  J W Warburton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1967-08       Impact factor: 10.154

2.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

3.  Effects of L-dopa in Parkinson's disease.

Authors:  R B Godwin-Austen; E B Tomlinson; C C Frears; H W Kok
Journal:  Lancet       Date:  1969-07-26       Impact factor: 79.321

4.  Treatment of parkinsonism with L-dopa (study of 105 patients).

Authors:  H L Klawans; J S Garvin
Journal:  Dis Nerv Syst       Date:  1969-11

5.  The measurement of memory in clinical practice.

Authors:  M Williams
Journal:  Br J Soc Clin Psychol       Date:  1968-02

6.  W.A.I.S. scores in a group of Parkinson patients.

Authors:  D Asso
Journal:  Br J Psychiatry       Date:  1969-05       Impact factor: 9.319

7.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

8.  Memory disturbance and the Parkinson syndrome.

Authors:  J W Warburton
Journal:  Br J Med Psychol       Date:  1967-06

9.  Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

Authors:  F McDowell; J E Lee; T Swift; R D Sweet; J S Ogsbury; J T Kessler
Journal:  Ann Intern Med       Date:  1970-01       Impact factor: 25.391

10.  Treatment of Parkinsonism with Laevo-dopa.

Authors:  C Mawdsley
Journal:  Br Med J       Date:  1970-02-07
View more
  15 in total

Review 1.  Parkinson's disease and levodopa. A five-year follow-up and review.

Authors:  C H Markham; L J Treciokas; S G Diamond
Journal:  West J Med       Date:  1974-09

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

3.  [Influence of L-DOPA on night sleep in parkinsonian patients].

Authors:  K Kendel; U Beck; C Wita; E Hohneck; H Zimmermann
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1972

4.  Effects of levodopa therapy in Parkinson's disease. II. Measurement of behavioural changes.

Authors:  R Radbill; G Rosenberg; A Schwartz
Journal:  Can Med Assoc J       Date:  1974-12-07       Impact factor: 8.262

5.  [General intelligence of patients with parkinsonism during L-dopa medication (author's transl)].

Authors:  P Jacobi; P A Fischer; E Schneider
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974

6.  Effect of L-dopa on delayed response and visual discrimination in cats and its relation to brain chemistry.

Authors:  A Kitsikis; A G Roberge; G Frenette
Journal:  Exp Brain Res       Date:  1972       Impact factor: 1.972

Review 7.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

8.  L-dopa and arousal.

Authors:  T B Horvath; R A Meares
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

9.  Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

Authors:  B Pillon; B Dubois; G Cusimano; A M Bonnet; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

10.  Confusion, dementia and anticholinergics in Parkinson's disease.

Authors:  Y de Smet; M Ruberg; M Serdaru; B Dubois; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.